Research status of HIV pre-exposure prophylaxis
10.19428/j.cnki.sjpm.2018.19118
- VernacularTitle:人类免疫缺陷病毒感染暴露前预防用药的研究现状
- Author:
Yu-Qin CAO
1
;
Rui-Jie CHANG
;
Hu-Wen WANG
;
Su-Ping WANG
;
Yong CAI
Author Information
1. 上海交通大学医学院
- Keywords:
HIV;
AIDS;
pre-exposure prophylaxis (PrEP);
research status;
strategy
- From:
Shanghai Journal of Preventive Medicine
2018;30(12):995-999
- CountryChina
- Language:Chinese
-
Abstract:
The efficacy, safety and adherence of HIV pre-exposure prophylaxis (PrEP) are reviewed in this article. Oral daily tenofovir/emtricitabine can significantly decrease the incidence of HIV infection among people at high risk, with no severe adverse effects. PrEP effectiveness is closely associated with medication adherence. To reduce the transmission of HIV, it is suggested that pilot tests should be carried out in high risk population; universal education offered on AIDS prevention and control; drug prices lowered; comprehensive prevention strategy adopted; marketing of PrEP drugs promoted; and the risk of HIV infection reduced.
